Overview

Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy using silicon phthalocyanine 4 may be effective against skin cancer. PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating participants with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.

Phase:

Phase 1

Details

Lead Sponsor:

Case Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Silicon
Silicon phthalocyanine